USPTO Allows Accelerated Path For COVID-19 Products Across Medical, Health Care Sectors
Executive Summary
USPTO pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months. Prioritized examination is available solely for small entities and would save them $2,000.
You may also be interested in...
COVID-19 Fraud In US: Online Pharmacies Promote HIV Drug, Ammo Dealer Pitches Vitamin C
Latest letters from website reviews push to 62 the number of warnings the FDA, either jointly with the FTC or on its own, has made stating that no drug has yet been approved by the agency for use in the prevention, diagnosis, treatment, mitigation or cure of COVID-19.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.